User:Mr. Ibrahem/Tagraxofusp

Tagraxofusp, sold under the brand name Elzonris, is an anti-cancer medication used to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN). It is given by gradual injection into a vein. Antihistamines and steroids are used to decrease t he risk of allergic reactions.

Common side effects include low albumin, liver problems, low platelets, nausea, tiredness, and fever. Other serious side effects may include capillary leak syndrome. Tagraxofusp is a fusion protein consisting of interleukin 3 (IL-3) fused to diphtheria toxin. The IL-3 attaches to BPDCN cells, resulting in their death.

Tagraxofusp was approved for medical use in the United States in 2018 and Europe in 2021. In the United States it costs about 29,000 USD for 1000 ug as of 2021.